GlaxoSmithKline requests emergency authorization from FDA for Covid antibody drug

Business

In this article

In this photo illustration the British multinational pharmaceutical company GlaxoSmithKline (GSK) logo seen displayed on a smartphone with a computer model of the COVID-19 coronavirus on the background.
Budrul Chukrut | SOPA Images | Getty Images

GlaxoSmithKline and Vir Biotechnology on Friday applied for an emergency use authorization from the Food and Drug Administration for their monoclonal antibody drug.

The FDA submission is based on an interim analysis of a phase three trial, which evaluated the drug for the early treatment of Covid-19 in adults at high risk of hospitalization. The drug reduced hospitalizations or death from Covid-19 by 85% compared with a placebo.

The two companies in August started testing the antibody on early-stage Covid-19 patients, hoping to keep symptoms from progressing.

This is a developing story. Please check back for updates.

-Reuters contributed to this report.

Articles You May Like

May 17 is your last chance to claim your 2020 tax refund — the median payment is $932, IRS says
Some vacationers expect to carry summer travel debt, report finds. Here’s how to avoid that
Peloton shares drop after it announces refinancing to stave off cash crunch
Netflix ad-supported tier has 40 million monthly users, nearly double previous count
Cisco reports better-than-expected results even as revenue suffers steepest drop in 15 years